Datametrex AI (TSXV: DM) has secured further test kits for its COVID-19 testing operation. The company this morning announced that it has secured exclusive rights to sell and distribute a COVID-19 saliva kit manufactured by Wizchem in both Canada and Saudi Arabia, as well as non-exclusive rights for the United Stated, the European Union, and the United Kingdom.
Labelled as the COVICHEK Saliva DNA/RNA Collection Kit, as well as the associated transport medium, the test kit has secured US FDA Emergency Use Authorization, as well as the CE Mark designation which enables sales within the European Union. The product is also GMP compliant.
While not currently approved for use in Canada, the test kits will be submitted to Health Canada for approval on a fast track basis. They will also be submitted to the Saudi Food & Drug Authority for approval for use in the Kingdom of Saudi Arabia on a fast tracked basis.
“Datametrex has been awarded another incredible opportunity to secure an additional medical testing device supplier from South Korea with WIZCHEM. With the second wave of COVID-19 in the United States and throughout the world, we at Datametrex believes an increase in testing capacity is critical to test, track and protect populations.”
Marshall Gunter, CEO of Datametrex AI
No consideration was paid to Wizchem to acquire the sales rights of the test kits.
Datametrex AI last traded at $0.155 on the TSX Venture.
FULL DISCLOSURE: DataMetrex AI Limited is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DataMetrex AI Limited on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
